Founded in 2009, the Bellevue-based company is led by Oraya Therapeutics founder Michael Gertner. Kona’s technology is dubbed “Surround Sound” since it utilizes ultrasound from outside the body in order to treat nerves around the kidney and reduce hypertension. The company said that clinical studies have shown that ablation of renal nerves can lead to reductions in high blood pressure.
“These funds are earmarked for the China market,” Gertner said in a statement. “Our research predicts a very large market in China for a non-invasive therapy to treat hypertension. This investment will allow Kona to begin navigating the complex clinical, regulatory, and intellectual property issues associated with this region.”